Tags

Type your tag names separated by a space and hit enter

Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration.
J Surg Oncol. 2013 May; 107(6):665-72.JS

Abstract

Post-operative management of differentiated thyroid cancer (DTC) often involves administration of radioactive iodine (RAI) for remnant ablation or adjuvant therapy. However, given the favorable prognosis associated with DTC, the risk versus benefit ratio of RAI remains unclear. RAI is associated with substantial, albeit rare side effects, including a possible increased risk of secondary malignancy and altered fertility, which must be balanced against the magnitude of benefit for decreasing recurrence and improving survival.

Authors+Show Affiliations

Division of Breast/Soft Tissue and Endocrine Surgery, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

23192391

Citation

Patel, Supriya S., and Melanie Goldfarb. "Well-differentiated Thyroid Carcinoma: the Role of Post-operative Radioactive Iodine Administration." Journal of Surgical Oncology, vol. 107, no. 6, 2013, pp. 665-72.
Patel SS, Goldfarb M. Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration. J Surg Oncol. 2013;107(6):665-72.
Patel, S. S., & Goldfarb, M. (2013). Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration. Journal of Surgical Oncology, 107(6), 665-72. https://doi.org/10.1002/jso.23295
Patel SS, Goldfarb M. Well-differentiated Thyroid Carcinoma: the Role of Post-operative Radioactive Iodine Administration. J Surg Oncol. 2013;107(6):665-72. PubMed PMID: 23192391.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration. AU - Patel,Supriya S, AU - Goldfarb,Melanie, Y1 - 2012/11/28/ PY - 2012/06/13/received PY - 2012/10/26/accepted PY - 2012/11/30/entrez PY - 2012/11/30/pubmed PY - 2013/6/12/medline SP - 665 EP - 72 JF - Journal of surgical oncology JO - J Surg Oncol VL - 107 IS - 6 N2 - Post-operative management of differentiated thyroid cancer (DTC) often involves administration of radioactive iodine (RAI) for remnant ablation or adjuvant therapy. However, given the favorable prognosis associated with DTC, the risk versus benefit ratio of RAI remains unclear. RAI is associated with substantial, albeit rare side effects, including a possible increased risk of secondary malignancy and altered fertility, which must be balanced against the magnitude of benefit for decreasing recurrence and improving survival. SN - 1096-9098 UR - https://www.unboundmedicine.com/medline/citation/23192391/Well_differentiated_thyroid_carcinoma:_the_role_of_post_operative_radioactive_iodine_administration_ L2 - https://doi.org/10.1002/jso.23295 DB - PRIME DP - Unbound Medicine ER -